Zai Lab (ZLAB) said Friday that its new drug application for KarXT to treat adult patients with schizophrenia was accepted by China's National Medical Products Administration.
The application is backed by results from a phase 1 China pharmacokinetics study, the phase 3 China study and data from global Emergent clinical programs, according to the company.
KarXT, or xanomeline and trospium chloride, showed a reduction in positive and negative syndrome scale total score from baseline in the China phase 3 study, Zai Lab added.
Shares of Zai Lab were up 2.1% in recent trading.
Price: 25.91, Change: +0.53, Percent Change: +2.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments